A Multicentre, Open-Label, Exploratory Phase Ib Clinical Study to Assess Safety and Efficacy of an EGFR Tyrosine Kinase Inhibitor in Combination With EGF Pathway Targeting Immunisation (EGF-PTI) in Treatment-Naïve Patients With EGFR Mutant NSCLC. The EPICAL Study
Latest Information Update: 04 Jul 2022
At a glance
- Drugs Afatinib (Primary) ; BV NSCLC 001 (Primary) ; Cyclophosphamide
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms EPICAL
- 29 Jun 2022 Status changed from discontinued to completed.
- 01 Feb 2022 Results published in the Lung Cancer
- 14 Sep 2021 Status changed from active, no longer recruiting to discontinued as per results presented at the 2021 World Conference on Lung Cancer